WNK463|2012607-27-9|-陌孚医药/Medlife

您当前的位置：

WNK463

目录号: PL11220 纯度: ≥99%

CAS No. :2012607-27-9

商品编号	规格	价格	会员价
PL11220-1mg	1mg	¥1236.36	请登录
PL11220-5mg	5mg	¥2225.45	请登录
PL11220-10mg	10mg	¥3214.55	请登录
PL11220-25mg	25mg	¥5934.55	请登录
PL11220-50mg	50mg	¥9396.36	请登录
PL11220-100mg	100mg	¥14836.36	请登录
PL11220-200mg	200mg	询价	询价
PL11220-500mg	500mg	询价	询价
PL11220-10mM*1mLinDMSO	10mM*1mLinDMSO	¥2274.91	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称	WNK463
中文别名	N-叔丁基-1-[1-[5-[5-(三氟甲基)-1,3,4-恶二唑-2-基]-2-吡啶基]-4-哌啶基]-1H-咪唑-5-甲酰胺
英文名称	WNK463
英文别名	WNK463;WNK-463;N-Tert-Butyl-1-(1-{5-[5-(Trifluoromethyl)-1,3,4-Oxadiazol-2-Yl]pyridin-2-Yl}piperidin-4-Yl)-1h-Imidazole-5-Carboxamide;N-tert-butyl-1-(1-(5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)piperidin-4-yl)-1H-imidazole-5-carboxamide;N-(tert-butyl)-1-(1-(5-(5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl)pyridin-2-yl)piperidin-4-yl)-1H-imidazole-5-carboxamide;BCP29014;s8358;AK685668;J3.591.084K;5FJ;N-Tert-butyl-3-[1-[5-[5-(trifluoromethyl)-1,3,4-oxadiazol-2-yl]pyridin-2-yl]piperidin-4-yl]imidazole;WNK 463
Cas No.	2012607-27-9
分子式	C₂₁H₂₄F₃N₇O₂
分子量	463.46
包装储存	Powder -20°C 3 years；4°C 2 years

产品详情	WNK463 是一种口服的 WNK 激酶抑制剂，对于WNK1，WNK2，WNK3 和 WNK4 的 IC₅₀ 值分别为 5 nM，1 nM，6 nM 和 9 nM。
生物活性	WNK463 is an orally bioavailable pan-With-No-Lysine (K) (WNK)-kinase inhibitor with IC 50s of 5 nM, 1 nM, 6 nM, and 9 nM for WNK1, WNK2, WNK3, and WNK4, respectively.
性状	Solid
IC50 & Target[1][2]	IC50: 5 nM (WNK1), 1 nM (WNK2), 6 nM (WNK3), and 9 nM (WNK4)
体外研究(In Vitro)	WNK463 (50 nM, 1 μΜ, 10 μΜ; 6 days; Human tissue-engineered corneas (hTECs)) treatment reduces phosphorylation of the WNK1 downstream targets SPAK/OSR1 in wounded hTECs. has not independently confirmed the accuracy of these methods. They are for reference only.Western Blot Analysis
体内研究(In Vivo)	WNK463 (1-10 mg/kg; oral administration; 4 hours; Spontaneously hypertensive Sprague Dawley rats) treatment produces dose-dependent decreases in blood pressure and simultaneous increases in heart rate in conscious SHRs. WNK463 produces significant and dose-dependent increases in urine output as well as urinary sodium and potassium excretion rates. WNK463 is orally bioavailable in Sprague Dawley rats with a half-life of 2.1 hours. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件	Room temperature in continental US; may vary elsewhere.
储存方式	Powder -20°C 3 years；4°C 2 years
参考文献	[1]. Yamada K et al. Small-molecule WNK inhibition regulates cardiovascular and renal function. Nat Chem Biol. 2016 Nov;12(11):896-898. [2]. Desjardins P, et al. Contribution of the WNK1 kinase to corneal wound healing using the tissue-engineered human cornea as an in vitro model. J Tissue Eng Regen Med. 2019 Sep;13(9):1595-1608.

溶解度数据	In Vitro: DMSO : ≥ 30 mg/mL (64.73 mM)配制储备液

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation